Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2018 2
2019 1
2020 1
2021 6
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, Müller-Tidow C, Raab MS, Bahlis NJ. Friedrich MJ, et al. Among authors: kilian m. Cancer Cell. 2023 Apr 10;41(4):711-725.e6. doi: 10.1016/j.ccell.2023.02.008. Epub 2023 Mar 9. Cancer Cell. 2023. PMID: 36898378 Free article.
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. Kilian M, et al. Cancer Cell. 2023 Feb 13;41(2):235-251.e9. doi: 10.1016/j.ccell.2022.12.007. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638785 Free article.
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, Günter M, Bunse T, Pusch S, von Deimling A, Wick W, Autenrieth SE, Prinz M, Platten M, Bunse L. Friedrich M, et al. Among authors: kilian m. Neuro Oncol. 2023 Feb 14;25(2):263-276. doi: 10.1093/neuonc/noac138. Neuro Oncol. 2023. PMID: 35609569 Free PMC article.
NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann DC, Boschert T, Koopmann P, Sanghvi K, De Roia A, Jung S, Jähne K, Day B, Shultz LD, Ratliff M, Harbottle R, Green EW, Will R, Wick W, Platten M, Bunse L. Krämer C, et al. Among authors: kilian m. Neuro Oncol. 2024 Feb 2;26(2):266-278. doi: 10.1093/neuonc/noad172. Neuro Oncol. 2024. PMID: 37715782 Free PMC article.
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.
Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Gegner HM, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana FJ, von Deimling A, Wick W, Prinz M, Platten M. Friedrich M, et al. Among authors: kilian m. Nat Cancer. 2021 Jul;2(7):723-740. doi: 10.1038/s43018-021-00201-z. Epub 2021 May 24. Nat Cancer. 2021. PMID: 35121943
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Bunse L, et al. Among authors: kilian m. Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9. Nat Med. 2018. PMID: 29988124
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, von Deimling A, Wick W, Sahm F, Platten M, Bunse L. Kilian M, et al. Clin Cancer Res. 2022 Jan 15;28(2):378-389. doi: 10.1158/1078-0432.CCR-21-1881. Epub 2021 Nov 15. Clin Cancer Res. 2022. PMID: 34782365 Free PMC article.
IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.
Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller SB, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, Friedrich MJ. Kehl N, et al. Among authors: kilian m. J Immunother Cancer. 2022 Oct;10(10):e005815. doi: 10.1136/jitc-2022-005815. J Immunother Cancer. 2022. PMID: 36252999 Free PMC article.
20 results